1. Underrepresentation of racial and ethnic minority groups in gynecologic oncology: An analysis of over 250 trials
- Author
-
Richardson, Michael T, Barry, Danika, Steinberg, Jecca R, Thirunavu, Vineeth, Strom, Danielle E, Holder, Kai, Zhang, Naixin, Turner, Brandon E, Magnani, Christopher J, Weeks, Brannon T, Young, Anna Marie P, Lu, Connie F, Wolgemuth, Tierney R, Laasiri, Nora, Squires, Natalie A, Anderson, Jill N, Karlan, Beth Y, Chan, John K, Kapp, Daniel S, Roque, Dario R, and Salani, Ritu
- Subjects
Reproductive Medicine ,Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Clinical Research ,American Indian or Alaska Native ,Ovarian Cancer ,Cancer ,Rare Diseases ,Clinical Trials and Supportive Activities ,Prevention ,Good Health and Well Being ,Humans ,Female ,United States ,Genital Neoplasms ,Female ,Ethnicity ,Ethnic and Racial Minorities ,Minority Groups ,Ovarian Neoplasms ,Uterine Neoplasms ,Gynecologic cancers ,Race and ethnicity ,Underrepresentation ,Trial enrollment ,Time trends ,Paediatrics and Reproductive Medicine ,Oncology & Carcinogenesis ,Clinical sciences ,Oncology and carcinogenesis ,Reproductive medicine - Abstract
ObjectiveTo describe the participation of racial and ethnic minority groups (REMGs) in gynecologic oncology trials.MethodsGynecologic oncology studies registered on ClinicalTrials.gov between 2007 and 2020 were identified. Trials with published results were analyzed based on reporting of race/ethnicity in relation to disease site and trial characteristics. Expected enrollment by race/ethnicity was calculated and compared to actual enrollment, adjusted for 2010 US Census population data.Results2146 gynecologic oncology trials were identified. Of published trials (n = 252), 99 (39.3%) reported race/ethnicity data. Recent trials were more likely to report these data (36% from 2007 to 2009; 51% 2013-2015; and 53% from 2016 to 2018, p = 0.01). Of all trials, ovarian cancer trials were least likely to report race/ethnicity data (32.1% vs 39.3%, p = 0.011). Population-adjusted under-enrollment for Blacks was 7-fold in ovarian cancer, Latinx 10-fold for ovarian and 6-fold in uterine cancer trials, Asians 2.5-fold in uterine cancer trials, and American Indian and Alaska Native individuals 6-fold in ovarian trials. Trials for most disease sites have enrolled more REMGs in recent years - REMGs made up 19.6% of trial participants in 2007-2009 compared to 38.1% in 2016-2018 (p
- Published
- 2024